Market capitalization | $204.72m |
Enterprise Value | $165.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 11.86 |
P/S ratio (TTM) P/S ratio | 14.70 |
P/B ratio (TTM) P/B ratio | 2.56 |
Revenue growth (TTM) Revenue growth | 577.76% |
Revenue (TTM) Revenue | $13.93m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
3 Analysts have issued a Vaxart, Inc. forecast:
3 Analysts have issued a Vaxart, Inc. forecast:
Jun '24 |
+/-
%
|
||
Net Profit | -16 -16 |
27%
27%
|
|
Depreciation and Amortization | 1.10 1.10 |
3%
3%
|
|
Stock Compensation | 2.56 2.56 |
35%
35%
|
|
Operating Cash Flow | -12 -12 |
31%
31%
|
|
Investments | 0.37 0.37 |
18%
18%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -12 -12 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.
Head office | United States |
CEO | Steven Lo |
Employees | 125 |
Founded | 2004 |
Website | www.vaxart.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.